Arkadios Wealth Advisors Buys 524 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Arkadios Wealth Advisors raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,295 shares of the company’s stock after buying an additional 524 shares during the period. Arkadios Wealth Advisors’ holdings in CRISPR Therapeutics were worth $531,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in CRSP. Riggs Asset Managment Co. Inc. increased its stake in CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. SFE Investment Counsel increased its position in shares of CRISPR Therapeutics by 3.6% during the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after purchasing an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of CRISPR Therapeutics by 4.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after buying an additional 211 shares in the last quarter. Orion Capital Management LLC lifted its position in CRISPR Therapeutics by 44.0% in the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after buying an additional 220 shares during the last quarter. Finally, National Bank of Canada FI boosted its stake in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 1.5 %

Shares of NASDAQ CRSP opened at $48.94 on Wednesday. The firm has a fifty day simple moving average of $47.18 and a two-hundred day simple moving average of $52.60. The firm has a market capitalization of $4.16 billion, a PE ratio of -17.99 and a beta of 1.68. CRISPR Therapeutics AG has a 12 month low of $38.16 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.98) EPS. On average, sell-side analysts predict that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CRSP shares. Truist Financial decreased their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Needham & Company LLC decreased their price objective on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Rodman & Renshaw began coverage on CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price for the company. Finally, Barclays reduced their price target on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $75.19.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.